Trial | NCT02518932  Report issue

Official Title

The Effect of VTC-G15 (a Pentapeptide Cleavage Product og GLP-1) on Whole Body Glucose Metabolism in Man

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    20
To asses the modulating properties of the cleaved pentapeptide product of GLP-1 amide.
The investigators have previously demonstrated that infusion of the pentapeptide during hyperglycemic clamps in dogs significantly increases the glucose infusion rate necessary to maintain stable hyperglycemia without any significant differences in insulin or glucagon secretion. The present study's aim is to examine whether this also occurs in humans. It may be necessary to examine a dose response curve. Specifically, in twenty healthy volunteers glucose infusion rate during the peptide infusion will be compared to the glucose infusion rate during saline administration during a 4 hour hyperglycemic clamp, in a cross over design(mg/kg/min).
Study Started
Mar 31
2015
Primary Completion
Mar 31
2016
Anticipated
Study Completion
Mar 31
2016
Anticipated
Last Update
Aug 10
2015
Estimate

Drug Last 5 amino acids of GLP-1

To examine insulinomimetic properties of LVKGR

  • Other names: VTC-G15; LVKGR

Drug placebo saline

Drug GLP-1 (32-36) Amide Experimental

To examine insulinomemtic of the last 5 amino acids of GLP-1 from 60-180 min during a 4 hour hyperglycemic clamp

Placebo Placebo Comparator

To examine the effect of saline on glucose uptake

Criteria 

Inclusion Criteria:

BMI 18.5-25;
33-38

Exclusion Criteria:

T2D
T1D
Hypoglycemic agents
No Results Posted